Hot topics in Parkinson’s disease research from AAN Virtual 2022

Recent research findings in Parkinson’s disease from the AAN Virtual 2022 poster session ranged from new diagnostic tools using cervical skin biopsies to the benefits of mindfulness-based interventions.

Making the diagnosis

Significant overlap between the clinical features of Parkinson’s disease (PD), multiple system atrophy (MSA) and progressive supranuclear palsy (PSP) can make diagnosis a challenge. Olszewska and colleagues1 reported their novel Real-Time Quaking-induced Conversion (RT-QuIC) protocol that enables rapid detection of alpha-synuclein in cerebrospinal fluid using a minimally invasive cervical skin biopsy. Combining the results with serum neurofilament light chain measurement achieved 100% sensitivity/100% specificity in distinguishing MSA from PD and 100% sensitivity/93% specificity for MSA versus PD/PSP/healthy controls.

Combining the results achieved 100% sensitivity/100% specificity in distinguishing MSA from PD

 

Could smell therapy improve apathy?

In Alzheimer’s disease and mild cognitive impairment there appears to be an association between olfactory dysfunction and apathy, which share anatomical pathways, suggesting smell therapy as a potential therapeutic approach for apathy. Nunez and colleagues2 were interested if there was a similar relationship in PD, using data from 486 patients with PD followed for 5 years in the Parkinson’s Progression Markers Initiative Study. They found no association between apathy and olfactory dysfunction, no difference in olfaction between patients with and without apathy, and no difference between patients with and without olfactory dysfunction in their time to develop apathy (all p>0.05). This highlights the clinical heterogeneity in neurodegenerative disorders.

They found no association between apathy and olfactory dysfunction

 

Training the mind and the gait

Shaji and colleagues3 were interested in the use of mindfulness-based interventions (MBI) for newly diagnosed patients with PD. They enrolled 25 patients for an 8-week program, with assessment using a number of measurement instruments at baseline, 8 weeks and 3 months. There was significant improvement in both motor and neuropsychiatric deficits, with increased mindfulness and emotional wellbeing and reduced stress. These were seen immediately following the MBI and maintained at 3-month follow-up.

Significant improvement in both motor and neuropsychiatric deficits

Gait training is an important part of rehabilitation for patients with PD. Amin et al.4 studied factors influencing the response to a 10-week gait training program in 19 patients. Greater improvements in gait speed in unadjusted and age-adjusted models were independently associated with better baseline memory performance and lower MDS-UPDRS Part III scores, but not with baseline executive function. The authors suggested that memory may be more important than other cognitive domains in effective gait rehabilitation, and degree of motor involvement will also influence the response.

Memory may be more important than other cognitive domains in effective gait rehabilitation

 

It’s a team game

Specialized physiotherapy (PT) reduces complications and healthcare costs for patients with PD. Talebi and colleagues5 looked at whether this was also true for specialized occupational therapy (OT) and speech and language therapy (SLT). Their retrospective observational study of 51,464 patients with PD used healthcare expenditure data from the Netherlands. The authors confirmed the inverse association between specialized PT and the incidence of complications and demonstrated this was also true for specialized OT. A similar trend for specialized SLT was not statistically significant.

Inverse association between specialized PT and OT and the incidence of complications

Our correspondent’s highlights from the symposium are meant as a fair representation of the scientific content presented. The views and opinions expressed on this page do not necessarily reflect those of Lundbeck.

References
  1. Olszewska DA, Martinez-Valbuena I, Visanji N, et al. A rapid, ultra-sensitive, RT-QuIC assay, with novel protocol, for MSA and PD using a single site skin biopsy and serum neurofilament light chain. Poster presented at: American Academy of Neurology Annual Meeting; 2022 Apr 24-26; Virtual.
  2. Nunez AEM, Latack K, Situ-Kcomt M, Mahajan A. Olfaction and apathy in early Parkinson’s disease. Poster presented at: American Academy of Neurology Annual Meeting; 2022 Apr 24-26; Virtual.
  3. Shaji A, Ko N, Lasker A. Mindfulness based program for newly diagnosed Parkinson’s patients. Poster presented at: American Academy of Neurology Annual Meeting; 2022 Apr 24-26; Virtual.
  4. Amin R, Phillips J, Humbert A, et al. Associations between Baseline Cognitive Function and Gait Outcomes after Treadmill Training in Parkinson disease. Poster presented at: American Academy of Neurology Annual Meeting; 2022 Apr 24-26; Virtual.
  5. Talebi AH, Ypinga J, Munneke M, et al. Unraveling the Potential of Specialized Allied Health Therapy in Parkinson’s Disease. Poster presented at: American Academy of Neurology Annual Meeting; 2022 Apr 24-26; Virtual.
You are leaving Progress in Mind
Hello
Please confirm your email
We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.
The information on this site is exclusively intented for health care professionals.
All the information included in the Website is related to products of the local market and, therefore, directed to health professionals legally authorized to prescribe or dispense medications with professional practice. The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.
Congress
Register for access to Progress in Mind in your country